Evaluation of Intervention on Impaired Glucose Tolerance(IGT) in Patients With Coronary Heart Disease.
NCT ID: NCT00724542
Last Updated: 2008-08-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
1600 participants
INTERVENTIONAL
2008-07-31
2010-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control
Placebo with lifestyle intervention
No interventions assigned to this group
Drug
Voglibose tablets with lifestyle intervention
Voglibose tablets
0.2mg Tid
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Voglibose tablets
0.2mg Tid
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Impaired Glucose Tolerance
Exclusion Criteria
* Diabetes Mellitus
* Scr \> 2.0 mg/dL（176 μmol/L）
* ALT or AST \> 2.5 ULN
* Hb \< 90g/L
* Heart Failure
* Infection
* Undergo other interventional clinical trial
40 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Takeda
INDUSTRY
Ministry of Science and Technology of the People´s Republic of China
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Peking University First Hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Wenhui Ding, Professor
Role: PRINCIPAL_INVESTIGATOR
Peking University First Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Peking University First Hospital
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Wenhui Ding, Professor
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2006BAI01A02-11
Identifier Type: -
Identifier Source: org_study_id